Peter Attia Longevity: How a Regular Patient Gets Access to Similar Protocols

Who Is Peter Attia and Why Does His Protocol Matter?

Peter Attia is a Stanford- and Johns Hopkins-trained physician who left a surgical oncology track to build a practice centered on extending what he calls "healthspan," not just lifespan. His podcast "The Drive" has published more than 300 episodes interviewing researchers from the National Institute on Aging, trial investigators, and clinicians. That reach means his personal protocol gets dissected in patient forums, Reddit threads, and physician group chats with unusual intensity.

His influence matters clinically because he names specific drugs, doses, and labs publicly. Patients arrive at primary care offices asking for ApoB testing or rapamycin prescriptions. Physicians need to know the evidence base, or the lack of one, behind each item.

What Attia Has Said Publicly

Attia has discussed his protocol on multiple podcast episodes and in his 2023 book "Outlive." He has stated he takes rapamycin on an intermittent weekly schedule, has used and later discontinued metformin after reviewing its potential interference with exercise adaptation, and monitors testosterone levels with replacement therapy. He is explicit that his personal choices are not medical advice and that many of these interventions are off-label.

Why "Celebrity Protocol" Coverage Requires Clinical Framing

This article treats Attia's publicly disclosed practices as a starting point for evidence review, not as endorsement. Each drug discussed below is assessed against peer-reviewed trial data and current guideline statements.

Rapamycin: The Centerpiece of Attia's Longevity Stack

Rapamycin (sirolimus) is the drug most closely associated with Attia's longevity approach. The mechanistic rationale centers on mTOR (mechanistic target of rapamycin) inhibition. Blocking mTOR signaling activates autophagy, a cellular recycling process tied to reduced cellular senescence in multiple animal models.

Animal and Preclinical Evidence

The Interventions Testing Program (ITP), a National Institute on Aging-funded consortium, showed that rapamycin extended median lifespan by 9-14% in genetically heterogeneous mice even when started at an age equivalent to 60 years in humans. That finding was published in Nature and replicated across three independent sites. 1

A 2014 follow-up from the ITP confirmed dose-dependent lifespan extension and found female mice responded more strongly than males. 2 These are the most cited preclinical data in the longevity-medicine community.

Human Evidence: What We Actually Have

Human evidence is much thinner. A randomized trial by Mannick et al. Published in Science Translational Medicine (N=218, elderly volunteers) found that the rapalog everolimus at low doses improved influenza vaccine response by approximately 20% and reduced the rate of infections over one year. 3 That study is often cited as proof-of-concept for immune rejuvenation, though it used everolimus, not rapamycin, and was not a lifespan trial.

No randomized controlled trial has demonstrated that rapamycin extends human lifespan. The PEARL trial (Participatory Evaluation of Aging with Rapamycin for Longevity), a small pilot study, is ongoing as of 2025 and will report biomarker data, not mortality endpoints.

Dosing in the Longevity Context

Attia has publicly described intermittent dosing, typically 5-10 mg once weekly, rather than the daily dosing used in transplant immunosuppression. The intermittent schedule is hypothesized to limit side effects such as impaired wound healing and dyslipidemia that appear with continuous transplant doses. This hypothesis has biological plausibility but has not been validated in a controlled human trial.

The FDA approved sirolimus (Rapamune) for prophylaxis of organ rejection in renal transplantation. 4 Its use for longevity is explicitly off-label.

Metformin: Why Attia Stopped and What the Evidence Says

Metformin is the world's most-prescribed glucose-lowering drug and, for years, was part of Attia's personal stack. He reversed that decision publicly, citing a 2022 study showing that metformin blunted the mitochondrial adaptation normally produced by aerobic exercise.

The Exercise Interference Question

Walton et al. (2019, Aging Cell, N=53 older adults) found that metformin attenuated the increase in mitochondrial respiration and VO2 max that followed 12 weeks of aerobic exercise training. 5 Attia cited this type of data as the reason he discontinued metformin personally, given that exercise performance is central to his longevity framework.

A second paper by Konopka et al. Similarly reported that metformin reduced skeletal muscle mitochondrial content gains from endurance training in older adults. 6 The effect size matters: the blunting was roughly 45% compared to placebo.

TAME Trial: The Definitive Human Aging Study

The TAME trial (Targeting Aging with Metformin), funded by the American Federation for Aging Research and registered at ClinicalTrials.gov (NCT03138005), is enrolling 3,000 adults aged 65-79 to test whether metformin 1,500 mg/day delays the composite of incident chronic disease, disability, dementia, and death. Results are expected in the mid-2020s. 7

The American Diabetes Association 2024 Standards of Care state that metformin "remains the preferred initial pharmacologic agent" for type 2 diabetes management. 8 Its use in non-diabetic adults for aging is off-label pending TAME results.

Testosterone Optimization: The Hormonal Foundation

Attia is open about monitoring testosterone and using replacement therapy as needed. Low testosterone in men correlates with increased all-cause mortality risk in observational data. A meta-analysis published in JAMA Network Open (2019, 11 cohorts, N=24,109 men) found that men with total testosterone below 300 ng/dL had a 35% higher risk of all-cause mortality compared to eugonadal men over a median 9.7-year follow-up. 9

What the TRAVERSE Trial Changed

The TRAVERSE trial (N=5,246 men with hypogonadism and high cardiovascular risk, median follow-up 33 months) found that testosterone replacement therapy was non-inferior to placebo for major adverse cardiovascular events, settling a decade of debate about cardiac safety. 10 The Endocrine Society 2018 guideline recommends testosterone therapy for men with "consistently low serum testosterone concentrations and signs and symptoms of androgen deficiency." 11

Practical Access for Patients

A patient seeking testosterone evaluation needs a morning total testosterone level (drawn 7-9 AM), ideally with free testosterone, LH, FSH, and a complete metabolic panel. Any testosterone below 300 ng/dL in the presence of symptoms (fatigue, reduced libido, loss of muscle mass) meets most guideline thresholds for treatment consideration.

Continuous Glucose Monitoring and Metabolic Diagnostics

Attia advocates CGM use in non-diabetic adults to identify post-meal glucose spikes that standard fasting glucose misses. A 2021 study in Nature Metabolism (N=25 healthy adults) showed that time-in-range above 140 mg/dL varied sixfold between individuals eating identical meals, illustrating why population-level dietary advice may not capture individual metabolic responses. 12

ApoB and Lp(a): The Lipid Markers He Prioritizes

Standard LDL-C can underestimate cardiovascular risk, particularly in patients with insulin resistance. ApoB (apolipoprotein B) counts every atherogenic particle and is the metric Attia consistently cites. The European Atherosclerosis Society 2022 consensus statement recommends ApoB as the "primary lipid target" for cardiovascular risk assessment. 13

Lp(a) (lipoprotein(a)) is genetically determined in roughly 90% of its variance and elevated in 20% of the population. The European Society of Cardiology 2019 guidelines recommend measuring Lp(a) at least once in every adult. 14

DEXA and VO2 Max Testing

Attia's framework places DEXA body composition scans and VO2 max testing as baseline diagnostics. VO2 max is the single strongest predictor of all-cause mortality in observational data. A prospective study in JAMA Network Open (N=122,007, median follow-up 8.4 years) found that patients in the lowest VO2 max quintile had a 5-fold higher mortality risk than those in the highest quintile. 15

Zone 2 Training and the Exercise Foundation

No drug in Attia's stack is discussed without the caveat that exercise is the foundation. Zone 2 cardio, defined as the intensity at which lactate remains below approximately 2 mmol/L and conversational speech is just possible, is his primary recommendation for metabolic health.

A randomized trial published in Cell Metabolism (2019, N=72 sedentary adults) found that high-volume endurance training for 12 weeks produced the largest gains in mitochondrial function of any exercise modality tested, outperforming HIIT for mitochondrial biogenesis markers. 16 Attia cites 3-4 hours of Zone 2 weekly as a minimum for meaningful mitochondrial benefit.

Low-Dose Naltrexone and DHEA: The Smaller Pieces

Attia has mentioned low-dose naltrexone (LDN, typically 1.5-4.5 mg/night) and DHEA as components he has explored. LDN's proposed mechanism involves transient opioid receptor blockade leading to endorphin upregulation and potential immunomodulatory effects. A systematic review in Frontiers in Psychiatry (2018, 28 studies) found preliminary evidence for LDN in inflammatory and autoimmune conditions but noted most studies were small and uncontrolled. 17

DHEA supplementation in older adults has shown modest effects on bone mineral density and sexual function in randomized trials. A Cochrane review found no consistent benefit on cognitive function or overall wellbeing. 18 Both compounds remain off-label for longevity indications.

How a Regular Patient Actually Accesses These Protocols

Most patients cannot book an appointment with Attia directly. His practice, Early Medical, operates on a concierge model with a highly selective intake process. The practical question is whether similar care is accessible elsewhere.

Step 1: Start With Foundational Lab Work

Before any prescribing discussion, a physician needs a complete picture. The minimum panel to replicate Attia's diagnostic approach includes:

• Lipid panel with ApoB and Lp(a): ApoB target <80 mg/dL for high-risk patients per European Atherosclerosis Society guidance.
• Fasting glucose, insulin, and HbA1c: Detects pre-diabetes that standard fasting glucose misses.
• Total and free testosterone (men), plus estradiol: Morning draw required.
• Comprehensive metabolic panel: Liver and kidney function affect drug dosing.
• hsCRP and homocysteine: Inflammatory and methylation markers.

Most of these are available through standard primary care or direct-to-consumer lab services. Out-of-pocket cost for the full panel runs approximately $200-400 without insurance.

Step 2: Identify the Right Clinical Setting

Longevity-focused telehealth clinics have expanded significantly since 2020. A physician-supervised telehealth provider can prescribe rapamycin off-label, manage TRT, order CGM, and interpret advanced lipid panels. The key questions to ask any prospective provider:

• Is a board-certified physician (not just a nurse practitioner) reviewing every prescription?
• Does the clinic conduct baseline labs before prescribing?
• Is there a protocol for monitoring rapamycin's lipid and immune effects?

Primary care physicians can also order every diagnostic Attia recommends; the gap is typically time and familiarity with off-label longevity prescribing. Bringing published data, specifically the ITP rapamycin papers and the TRAVERSE testosterone trial, to an appointment can move the conversation forward.

Step 3: Understand the Off-Label Framework

Prescribing rapamycin for longevity is off-label. Under FDA regulations, physicians may prescribe approved drugs for unapproved uses based on their clinical judgment. 19 The prescribing physician bears responsibility for informed consent documenting that the patient understands the drug's approved indication and the investigational nature of longevity dosing.

Patients should expect to sign an informed consent form and to have baseline immune function, metabolic, and lipid panels repeated at 3-month intervals when starting rapamycin.

Step 4: Cost and Insurance Realities

Generic sirolimus costs approximately $50-150 per month at weekly doses of 5-6 mg through compounding pharmacies or GoodRx pricing. Insurance does not cover off-label use. CGM devices (Dexcom G7, Abbott Libre) cost roughly $75-150 per month out of pocket for non-diabetic users. Advanced lipid testing (ApoB, Lp(a)) may be covered under cardiovascular risk indications.

Testosterone therapy through telehealth, including labs, consultation, and medication, typically runs $100-250 per month depending on the delivery method (injections are least expensive; gels and pellets cost more).

What the Evidence Supports Versus What Requires More Data

Not every element of Attia's protocol has the same evidence quality. A clear-eyed read:

| Intervention | Evidence Grade | Regulatory Status | |---|---|---| | Zone 2 exercise (3-4 hrs/week) | Strong RCT and observational support | No prescription needed | | Testosterone replacement (hypogonadal men) | Strong RCT (TRAVERSE) and guideline support | FDA-approved, on-label | | Metformin (diabetic or pre-diabetic patients) | Strong RCT support for glucose outcomes | FDA-approved, on-label | | ApoB and Lp(a) testing | Guideline-endorsed biomarkers | Diagnostic, no Rx | | Rapamycin (weekly, longevity dosing) | Strong animal data; limited human RCTs | Off-label | | Metformin (non-diabetic aging adults) | TAME trial pending; exercise interference signal | Off-label | | Low-dose naltrexone | Preliminary, small studies only | Off-label | | DHEA | Mixed; modest effects in RCTs | OTC supplement in US |

Direct Quotes From Attia's Published Statements

In "Outlive" (2023), Attia writes that his goal is to function at age 80 the way an average healthy person functions at 65, framing longevity medicine as a proactive discipline rather than a reactive one. He states: "We want to delay the onset of chronic disease, and we want to maintain physical and cognitive function."

On rapamycin, Attia has said in podcast episodes that he views the ITP data as "the most compelling longevity data we have in any organism" while acknowledging that human trials are years away from delivering mortality endpoints. He consistently labels his personal use as an individual risk-benefit calculation, not a recommendation.

Risks, Monitoring, and What to Watch

Rapamycin at transplant doses causes immunosuppression, impaired wound healing, mouth sores, and dyslipidemia. At the lower weekly doses used in longevity protocols, these effects appear less frequent but are not absent. A case series published in Aging (2021, N=333 patients taking rapamycin off-label for longevity) found that 14% reported mouth sores, 12% reported mild infections, and lipid elevations occurred in approximately 20% of patients. 20

Monitoring protocol at minimum: CBC, comprehensive metabolic panel, and fasting lipids at baseline and every 3 months for the first year, then every 6 months if stable.

Men on testosterone replacement require hematocrit monitoring (target <54%) and PSA screening per Endocrine Society guidelines. 11